חוב לטווח קצר להון Precision BioSciences (DTIL)

Precision BioSciences is developing the gene therapy sector through alliances with global pharma behemoths. Current price action reflects the asset's status, where the indicator stands at 0.10. Precision BioSciences has created the unique ARCUS tool for high-precision correction of genetic defects without off-target mutations. The business currently relies exclusively on external financing and grants, as commercial products have not yet been brought to market.

This indicator assesses financial stability by comparing liabilities with a maturity of up to one year against total equity to determine liquidity risks. By analyzing the current short-term debt to equity value on the GURU.Markets platform, an investor can see the extent of Precision BioSciences (DTIL) dependence on rapid refinancing, which is critical when scaling the ARCUS platform in the field of gene editing and oncology therapy.